Hybrid compounds as new Bcr/Abl inhibitors
Authors:
- Deping WangDeping Wang
- Zhang ZhangZZZhang Zhang
- Xiaoyun LuXLXiaoyun Lu
- Yubing FengYFYubing Feng
- Kun LuoKLKun Luo
- Jirong GanJGJirong Gan
- Liu YingxueLYLiu Yingxue
- Junting WanJWJunting Wan
- Xiang LiXLXiang Li
- Fengxiang ZhangFZFengxiang Zhang
- Zhengchao TuZTZhengchao Tu
- Qian CaiQCQian Cai
- 1 April 2011
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (7) , 1965-1968
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemiaBlood, 2007
- Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemiaNature Reviews Cancer, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell, 2005
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973